Helping patients reclaim a life of possibility
Myeloma Patients Europe (MPE) is attending the International Myeloma Society (IMS) Annual Meeting in Athens, Greece, from 27 – 30 September. This year, the IMS meeting corresponds with European Myeloma Day, allowing us to engage with the whole myeloma community to mark this important event. The IMS Annual Meeting brings together myeloma experts from…
Myeloma Patients Europe (MPE) held a webinar to summarise the most important myeloma and AL amyloidosis updates presented at the European Hematology Association (EHA) hybrid 2023 congress. This congress was held in Frankfurt, Germany, in June 2023. The webinar took place on 6th July 2023 and was given by Prof. Dr. Mohamad Mohty, Professor and…
From T-cell collection to CAR T-cell infusion Myeloma Patients Europe (MPE) has conducted four written interviews on CAR-T manufacturing to better understand various myeloma CAR-T therapies’ manufacturing processes and challenges. Four stakeholders have answered our questions, including two pharmaceutical companies, each with a myeloma CAR-T product approved in the European Union, and two academic teams which have…
Myeloma Patients Europe (MPE) will host a webinar to summarise the most important myeloma and AL amyloidosis updates presented at the congress on 6 July 2023, from 17:00 – 18:00 CET, given by Prof. Dr. Mohamad Mohty, Professor and Head of the Hematology and cellular therapy department at the Saint-Antoine Hospital and Sorbonne University (Paris, France). If…
Myeloma Patients Europe (MPE) is pleased to announce it has been appointed to the new Health Technology Assessment (HTA) Stakeholder Network of the European Commission. This means that MPE will be actively engaged and consulted in the implementation of the EU HTA Regulation.
Myeloma Patients Europe (MPE) is pleased to announce that Katie Joyner and Kate Morgan have been appointed as joint Chief Executive Officers (CEO). The MPE Board of Directors unanimously made this decision based on the impressive work and leadership both have shown during the transition period following the stepping down of founding CEO, Ananda Plate.
One of the MPE Spanish members, the Spanish Amyloidosis Association (AMILO), last month celebrated its fifth anniversary by recognising the support and help other organisations have given them during these five years. MPE is pleased and proud to receive this recognition from AMILO at such an important event for our member. Along with MPE, other…
Funding for Daratumumab was recently approved in Israel for the treatment of newly diagnosed multiple myeloma (NDMM) patients in first line treatment, in large part thanks to a strong collaboration between the MPE Israeli member, AMEN, with local haematologists and pharmaceutical companies in Israel. “Health Basket” Each year, the Israel Ministry of Health nominates a Health…